周三，再鼎医药(ZLAB.US)股价走高，截至发稿，该股涨超7%，报18.84美元。该股港股今日收涨 6.24%。消息面上，再鼎医药宣布，中国国家药品监督管理局已批准呫诺美林曲司氯铵胶囊（凯捷乐） 的新药上市申请，用于治疗成人精神分裂症。这是70余年来首个获批的具有全新作用机制的精神分裂症 疗法，为精神分裂症治疗带来了根本性突破。 ...

智通财经APP获悉，周三，再鼎医药(ZLAB.US)股价走高，截至发稿，该股涨超7%，报18.84美元。该 股港股今日收涨6.24%。消息面上，再鼎医药宣布，中国国家药品监督管理局已批准呫诺美林曲司氯铵 胶囊（凯捷乐）的新药上市申请，用于治疗成人精神分裂症。这是70余年来首个获批的具有全新作用机 制的精神分裂症疗法，为精神分裂症治疗带来了根本性突破。 ...

| ZLAB 再鼎医药 | | | | --- | --- | --- | | 17 480 4 -0.230 -1.30% | | 收盘价 12/23 16:00 美东 | | 18.250 ↑ 0.770 +4.41% | | 盘前价 12/24 04:06 美东 | | 三 7 24 华 S 9 日 ♥ B | | ● 快捷交易 | | 最高价 18.095 | 开盘价 17.710 | 成交量 60.72元 | | 最低价 17.370 | 昨收价 17.710 | 成交额 1065.68万 | | 平均价 17.549 | 市盈率ITM 亏损 | 总市值 19.33亿 (…) | | 振 幅 4.09% | 市盈率(静) 亏损 | 总股本 1.11亿 | | 换手率 0.56% | 市净率 2.543 | 流通值 18.99亿 | | 52周最高 44.340 | 委 比 -26.32% | 流通股 1.09亿 | | 52周最低 16.820 | 量 比 0.46 | 色 主 1股 | | 历史最高 193.540 | 股息TTM -- | 换股比率 10.00 | | 历史最低 13.480 | ...

Market Overview - The Hong Kong stock market showed a positive atmosphere before Christmas, with all three major indices rising. The Hang Seng Index increased by 0.17% to close at 25,818.93 points, with a total turnover of HKD 92.524 billion [1] - CITIC Securities believes that after a one-sided rise in September, the Hong Kong stock market has experienced fluctuations since October due to changing overseas macro expectations. Currently, quality assets in the Hong Kong market are entering a high cost-performance ratio zone, supported by continuous capital inflow and improved profit expectations [1] Blue Chip Performance - Semiconductor company SMIC (00981) led the blue-chip stocks, rising by 3.12% to HKD 71.05, contributing 15.52 points to the Hang Seng Index. The company has implemented a price increase of approximately 10% on some of its production capacity [2][4] - Other notable blue-chip performances include China Hongqiao (01378) up 2.34%, and CK Infrastructure (01038) up 1.83%. However, Haier Smart Home (06690) and Alibaba Health (00241) saw declines of 2.32% and 1.53%, respectively [2] Sector Highlights - The semiconductor sector saw most stocks rise, with notable increases from companies like Jingmen Semiconductor (02878) up 3.53% and Huahong Semiconductor (01347) up 1.64%. The price increase by SMIC is attributed to rising raw material costs and strong demand driven by mobile applications and AI [3][4] - Nickel-related stocks were active, with Likin Resources (02245) rising by 11.44% and Xinjiang Xinmin Mining (03833) up 7.42%. This activity is linked to Indonesia's reduction in nickel production targets to stabilize prices [5] - Dairy stocks also performed well, with Yurun Dairy (09858) up 7.34% and Modern Dairy (01117) up 6.9%. The Chinese government's anti-subsidy measures on EU dairy imports are expected to enhance the competitive position of domestic dairy producers [6] Notable Stock Movements - Baiaosaitu-B (02315) saw a significant increase of 22.23% to HKD 35.08, following adjustments in the Hong Kong Stock Connect eligibility [7] - Yujian (02432) rebounded by 9.41% to HKD 31.62 after a recent unlock of shares, with the company launching a new AI-driven household robot [8] - Zai Ding Pharmaceutical (09688) rose by 6.24% to HKD 14.48 after receiving approval for a new schizophrenia treatment, marking a significant breakthrough in the field [9] - CGN Mining (01164) continued its upward trend, increasing by 5.02% to HKD 3.35, supported by forecasts of rising uranium prices [10]

Market Overview - The Hong Kong stock market showed a positive atmosphere before Christmas, with all three major indices rising. The Hang Seng Index increased by 0.17% to close at 25,818.93 points, with a total turnover of HKD 92.524 billion [1] - CITIC Securities noted that after a one-sided rise in September, the Hong Kong stock market experienced a period of adjustment in October due to fluctuating overseas macro expectations. Currently, high-quality assets in the Hong Kong market are entering a high cost-performance ratio zone, supported by continuous capital inflow and improved profit expectations [1] Blue Chip Performance - Semiconductor company SMIC (00981) led the blue-chip stocks, rising by 3.12% to HKD 71.05, contributing 15.52 points to the Hang Seng Index. Reports indicate that SMIC has implemented a price increase of approximately 10% on some production capacities [2][4] - Other notable blue-chip performances included China Hongqiao (01378) up 2.34%, and CK Infrastructure (01038) up 1.83%. However, Haier Smart Home (06690) and Alibaba Health (00241) saw declines of 2.32% and 1.53%, respectively [2] Sector Highlights - The semiconductor sector saw most stocks rise, with SMIC and Huahong Semiconductor (01347) also showing gains. The price increase by SMIC is attributed to rising raw material costs and strong demand driven by mobile applications and AI [3][4] - Nickel stocks were active, with Likin Resources (02245) rising by 11.44% and Xinjiang Xinmin Mining (03833) up 7.42%. This activity is linked to Indonesia's reduction in nickel production targets to stabilize prices [5] - Dairy stocks rose following the announcement of temporary anti-subsidy measures on EU dairy imports, benefiting domestic producers like Yurun Dairy (09858) and Modern Dairy (01117) [6] Notable Stock Movements - Baidu's stock (02315) surged by 22.23% after being added to the Hong Kong Stock Connect list, indicating strong market interest [7] - Robotics company Yujian (02432) rebounded by 9.41% following the release of its new AI-powered household robot, Rover X1 [8] - Zai Lab (09688) saw a 6.24% increase after receiving approval for a new schizophrenia treatment, marking a significant breakthrough in the field [9] - CGN Mining (01164) continued its upward trend, rising by 5.02%, supported by forecasts of rising uranium prices [10]

消息面上，12月23日，再鼎医药宣布，中国国家药品监督管理局已批准呫诺美林曲司氯铵胶囊（凯捷 乐）的新药上市申请，用于治疗成人精神分裂症。这是70余年来首个获批的具有全新作用机制的精神分 裂症疗法，为精神分裂症治疗带来了根本性突破。 公开资料显示，2021年11月，再鼎医药以1.87亿美元从Karuna Therapeutics获得了在大中华区开发、生 产和商业化呫诺美林曲司氯铵胶囊的独家授权。NMPA此次批准呫诺美林曲司氯铵胶囊是基于在中国开 展的Ⅰ期药代动力学研究、中国的Ⅲ期临床研究（ZL-2701-001）以及三项全球EMERGENT临床研究的 数据支持。 智通财经APP获悉，再鼎医药(09688)早盘涨超4%，截至发稿，涨3.45%，报14.1港元，成交额5919.14万 港元。 ...